Back to results
US 2014/0234390 A1Published application
Sustained drug delivery implant
AssigneeAllergan, Inc.
InventorsJane-Guo Shiah, Chetan Pujara
Life of this patent
Estimating the term…
Abstract
Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
Claims10
A solid intraocular implant for the treatment of a posterior ocular condition in a human patient, the solid intraocular implant comprising:
- a brimonidine free base in an amount of about 50% by weight of the implant, based on the total weight of the implant;
- and
- a biodegradable polymer matrix comprising a poly (D, L-lactide) polymer and a poly (D,L-lactide-co-glycolide) polymer.
A solid intraocular implant for the treatment of a posterior ocular condition in a human patient, the solid intraocular implant comprising:
- a brimonidine free base in an amount of about 40% by weight to 60% by weight of the implant, based on the total weight of the implant;
- and
- a biodegradable polymer matrix comprising an acid end-capped poly (D, L-lactide) polymer and a 75:25 poly (D,L-lactide-co-glycolide) polymer;
- wherein the weight ratio of the an acid end-capped poly (D, L-lactide) polymer to the 75:25 poly (D,L-lactide-co-glycolide) polymer is 1:1.
1 more element
Dependencies are inferred from the claim text.